Heron Therapeutics Q1 Earnings Call Highlights
Heron Therapeutics (NASDAQ:HRTX) said first-quarter 2026 results were pressured by seasonal factors and severe winter weather, but management reaffirmed its full-year outlook and pointed to improving momentum exiting the quarter. Chief Executive Officer Craig Collard said the company entered 2026 w
MarketBeat ·